[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-tract-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-tract-infections":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,43,0,25,[9,51,81,111,134,160,193,228,256,278,303,325,354,377,405,431,452,482,508,539,560,586,618,643,681],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100641920","antibiotic-irrigation-and-suction-ureteral-access-sheath-in-rirs-100641920",false,"NCT07655050","Antibiotic Irrigation and Suction Ureteral Access Sheath in RIRS","The Combined Effect of Antibiotic Irrigation and Aspiration Ureteral Access Sheath on Infectious Complications in Retrograde Intrarenal Surgery: A Prospective Randomized Factorial Study","Inclusion Criteria:\n\n* Patients scheduled for retrograde intrarenal surgery (RIRS) due to kidney stones\n* Male and female patients aged 18 years or older\n* Patients who voluntarily sign the informed consent form\n* Patients with sterile urine culture or whose preoperative infection has been treated and urine culture has become sterile\n\nExclusion Criteria:\n\n* Patients with active urinary tract infection before surgery\n* Patients with chronic kidney disease\n* Pregnant patients\n* Patients with allergy to aminoglycoside-group drugs used in the study protocol, specifically gentamicin\n* Cases in which the ureter cannot be accessed and the procedure is postponed by placing a double-J stent instead of performing dilation","ALL","18 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"NA","Retrograde intrarenal surgery (RIRS) is a widely used treatment for kidney stones; however, postoperative infectious complications remain a significant concern. This prospective randomized factorial trial aims to evaluate whether gentamicin-containing irrigation fluid and the use of a suction ureteral access sheath can reduce postoperative fever, systemic inflammatory response syndrome (SIRS), and sepsis after RIRS. The study will also investigate the independent and combined effects of these two interventions on infectious outcomes.",[27,28,29],"Kidney Calculi","Urolithiasis","Urinary Tract Infections",[31,32,33,34,35,36,37],"Retrograde intrarenal surgery","Kidney stone","Gentamicin","Irrigation fluid","Infectious complications","Urinary tract infection","SEPSİS","RECRUITING","2026-06-21",{"date":41,"type":42},"2026-06-24","ACTUAL",{"date":44,"type":42},"2026-06-15",{"date":46,"type":21},"2027-05-08",{"name":48,"class":49},"Hitit University","OTHER",2,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100635948","post-emergency-optimization-of-antibiotic-therapy-for-urinary-tract-infection-uti-100635948","NCT07559318","Post-Emergency Optimization of Antibiotic Therapy for Urinary Tract Infection (UTI)","Post-Emergency Optimization of UTI Antibiotic Therapy: \"Fluoroquinolones and Third-Generation Cephalosporins Under the Spotlight\"","REVIU48","Inclusion Criteria:\n\n* Age 18 years or over\n* Patients presenting at emergency department, with symptoms suggestive of a urinary tract infection suitable for outpatient management (uncomplicated cystitis or cystitis at risk of complications, uncomplicated pyelonephritis or pyelonephritis at risk of complications, male urinary tract infection with or without fever) who have had a urine culture taken\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Vulnerable person (person under guardianship or trusteeship, minor, person deprived of liberty, person unable to express their refusal)\n* Pregnant women\n* Severe urinary tract infection (sepsis, septic shock or requiring drainage, except for low urinary catheterisation)\n* Hospitalisation for a urinary tract infection or decompensation of another comorbidity\n* Suspected urinary tract infection without a urine culture having been performed",{"count":60,"type":21},330,"OBSERVATIONAL","Prospective, multicenter, non-interventional study conducted over 6 months, including patients presenting to the emergency department with suspected urinary tract infection managed as outpatients and discharged with or without empiric antibiotic therapy.\n\nDischarge antibiotic prescriptions are reviewed, with subsequent reassessment and optimization of treatment based on urine culture and susceptibility results",[29,64,65],"Antiobiotic Stewardship","Emerging Infectious Disease",[36,67,68,69,70],"Urine culture and sensitivity tests","Antimicrobial stewarship","Side effect and adverse event of antibiotics","Fluoroquinolones and 3rd-generation cephalosporins","2026-06-10",{"date":73,"type":42},"2026-06-12",{"date":75,"type":21},"2026-06-01",{"date":77,"type":21},"2027-01-01",{"name":79,"class":49},"Centre Hospitalier Intercommunal Creteil",3,{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":89,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100642142","phase-1-a-study-to-evaluate-gepotidacin-exposure-in-breast-milk-of-healthy-lactating-women-100642142","NCT07645235","A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women","A Phase 1 Open-Label, Single Dose Study to Evaluate the Pharmacokinetics of Gepotidacin in Healthy Lactating Women","Inclusion Criteria:\n\n* Participants must be healthy lactating women, 18 to 50 years of age, inclusive, at Screening.\n* Actively breastfeeding or expressing breast milk.\n* At least 28 days postpartum with a full milk supply established, and with no persistent complications from delivery (there is no maximal length of time postpartum required).\n* Willingness to temporarily discontinue feeding breast milk to infants from dosing through to 72 hours after dosing (approximately 3 days), with the ability to pump and provide reserve milk for bottle feeding prior to the study OR has decided to permanently discontinue breastfeeding but has not started weaning, provided the infant accepts bottle feeding and a sufficient milk supply is maintained by pumping 3 to 4 times daily, considering changes in milk composition during weaning process.\n* Is willing to fully express breast milk from both breasts during the duration of the milk collection portion of the study. Participants must be able to express milk from each breast at each pumping session using a breast pump.\n* Has a body mass index (BMI) of less than or equal to (\\\u003C=) 36 kilograms per meter square (kg\u002Fm\\^2) and weighs at least 45 kilograms (kg) with all clinical assessments considered as clinically non-significant per investigator.\n* Non-smoker (including vaping) or prior smokers (having smoked less than 10 cigarettes per day) who have stopped smoking for at least 1 month prior to screening.\n* Understands the study procedures and is capable of providing written informed consent.\n* A negative highly sensitive pregnancy test (\\[urine or serum\\] as required by local regulations) will be required at Baseline before the dose of study intervention.\n\nExclusion Criteria:\n\n* Participant is unwilling or unable to comply with the study restrictions or lifestyle guidelines presented in the protocol during the study period and through the post study visit.\n* History or evidence of any clinically significant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric (including post-natal depression), neurologic, infectious, neoplastic, active cancer or allergic disease (including drug allergies, but excluding untreated asymptomatic, seasonal allergies at time of dosing) or clinical findings that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the participant or infant by participation in the study.\n* Has had major surgery in the past 3 months (except delivery through a C section and\u002For tubal ligation).\n* History of significant multiple and\u002For severe allergies (including latex allergy, but with exception of seasonal rhinitis \\[hay fever\\]) or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food.\n* Hypersensitivity to gepotidacin.\n* Current or recent (less than \\[\\\u003C\\] 14 days) mastitis, or history of breast surgery (augmentation or reduction).\n* Use of any QT prolonging medications within 7 days prior to first dose, use of strong or moderate Cytochrome P450 3A4 (CYP3A4) inhibitors within 7 days prior to first dose, or use of strong or moderate CYP3A4 inducers (including vitamins, herbal and dietary supplements such as St. John's wort) within 14 days prior to first dose.\n* Currently a user of illicit drugs or has a history of drug (including alcohol) abuse within approximately 1 year.\n* Donated or lost 1 unit of blood (approximately 500 milliliters \\[mL\\]) or participated in another investigational study within 30 days or 5 half-lives of the investigational product prior to the screening. The 30 days window will be derived from the date of the last study procedure (i.e., poststudy, AE follow-up, etc.) in the previous study to the screening visit of the current study.\n* The participant has participated in a clinical trial and has received an investigational product within 30 days or 5 half-lives, whichever is longer.\n* Participants with excessive caffeine intake (defined as greater than \\[\\>\\] 6 servings \\[1 serving is approximately equivalent to 120 milligram \\[mg\\] of caffeine\\] of coffee, tea, cola or other caffeinated beverages per day) within 14 days prior to first dose.\n* The participant has known severe renal impairment (creatinine clearance \\\u003C30 milliliters per minute \\[mL\u002Fmin\\] or clinically significant elevated serum creatinine as determined by the investigator).\n* The participant presents with (self-reported) vaginal discharge suspected for infection at Baseline.\n* The participant has congenital long QT syndrome or known prolongation of the corrected QT (QTc) interval.\n* The participant has a family history of QT prolongation or sudden death.\n* The participant has a recent history of vasovagal syncope or episodes of symptomatic bradycardia or brady arrhythmia within the last 12 months.\n* Having two or more of the following risk factors: 1. Body weight between 45 kg and 60 kg, 2. Moderate renal impairment (creatinine clearance 30 to 59 mL\u002Fmin), 3. Moderate hepatic impairment (Child Pugh Class B)\n* QTc \\>450 milliseconds (msec) or QTc \\>480 msec for participants with bundle branch block.\n* Severe hepatic impairment (Child Pugh Class C)\n* Alanine aminotransferase \\>1.5\\*upper limit of normal (ULN).\n* Total bilirubin \\>1.5\\*ULN; Participants with Gilbert's syndrome can be included with total bilirubin \\>1.5\\*ULN if direct bilirubin is \\\u003C=1.5\\*ULN.\n* Current or chronic history of liver disease or known hepatic or biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones).",true,"FEMALE","50 Years",{"count":92,"type":21},8,[94],"PHASE1","This study aims to evaluate the pharmacokinetic of gepotidacin in fed healthy lactating women.",[29],[98,99,100],"Gepotidacin","Pharmacokinetics","Healthy Lactating Women","NOT_YET_RECRUITING","2026-06-08",{"date":73,"type":42},{"date":105,"type":21},"2026-07-09",{"date":107,"type":21},"2027-05-13",{"name":109,"class":110},"GlaxoSmithKline","INDUSTRY",{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100493921","double-voiding-and-post-transplant-uti-100493921","NCT05711446","Double Voiding and Post-transplant UTI","A Randomized Trial of Double Voiding Versus Usual Voiding to Reduce the Incidence of Urinary Tract Infections in Kidney Transplant Recipients","Inclusion Criteria:\n\n* All adult kidney transplant recipients who undergo routine follow-up at the New York Presbyterian - Weill Cornell Medicine (NYP-WCM) Transplant Clinic.\n\nExclusion Criteria:\n\n* Kidney transplant recipients who are discharged after a transplant with an indwelling catheter (Foley)",{"count":119,"type":21},438,[24],"Urinary tract infections (UTI) are common in kidney transplant recipients and are an important cause of illness and hospital admissions. Past studies have shown that about 1 out of 5 of newly transplanted patients develop UTI within their first 3 months of transplantation. Such UTIs increase the risk for blood stream infection and acute rejection of the kidney, Improvements in urinary voiding techniques may reduce the frequency of UTI. The purpose of this study is to evaluate the benefits of \"double voiding\" in kidney transplant recipients.",[29,123],"Kidney Transplant; Complications","2026-05-19",{"date":126,"type":42},"2026-05-22",{"date":128,"type":42},"2023-04-07",{"date":130,"type":21},"2027-05",{"name":132,"class":49},"Weill Medical College of Cornell University",1,{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":17,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":4},"100621500","phase-1-a-study-in-pediatric-participants-aged-2-to-12-years-with-a-suspected-or-confirmed-bacterial-infection-or-receiving-prophylaxis-antibiotics-100621500","NCT07371429","A Study in Pediatric Participants Aged ≥2 to \u003C12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics","Phase 1, Open-Label, Single Arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants From 2 to Less Than 12 Years of Age With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis With Antibiotics","Inclusion Criteria:\n\n* Participants having ≥2 to \\\u003C12 years of age at the time of signing the informed consent\u002Fassent and have a body weight \\>=10 kilograms (kg).\n* Participants receiving SoC antibacterial therapy for a confirmed\u002Fsuspected infection or for prophylaxis AND is able to take a single dose of the powder for oral suspension formulation of gepotidacin after a meal.\n* Participants either hospitalized or in an overnight clinic. Participant is expected to be in hospital\u002Fclinic for at least 24 hours post administration of study intervention.\n\nParticipant has an indwelling venous catheter in place as part of the clinical SoC.\n\n* Male or female according to their reproductive organs at birth.\n* Pregnancy testing is required as appropriate for the age, sexual activity, and sexual maturity of pediatric participants and as required by local regulations. Investigator should apply clinical judgment.\n* A female participant is eligible to participate if she is a WOCBP who is not pregnant as confirmed by a high sensitivity serum or urine pregnancy test at baseline (Day 1) regardless of current or prior contraception use or abstinence, is not breastfeeding, or is not a WOCBP.\n* Participant LAR(s) who has the ability to understand, agree to, and sign the informed consent form before initiation of any protocol-related procedures; participant has the ability to give documented assent.\n* Participant and participant's LAR are willing and able to comply with study instructions, study visits, and procedures.\n\nExclusion Criteria:\n\n* Participants having a BMI-for-age that is less than the 5th percentile or greater than the 95th percentile based on the CDC percentiles \\[CDC NCHS Growth Charts\\].\n* Participants having a clinically significant medical history, including malignancy, significant chromosome abnormality, neurological disorder or history of seizure (excluding simple febrile seizure), chronic immunosuppressive disease, active tuberculosis or acute hepatitis.\n* Participants with serious disease\u002Fcondition that could be imminently life-threatening (e.g. is clinically\u002Fhemodynamically unstable, is septicemic, has severe sepsis, organ failure, requiring ITU care or has clinical laboratory tests either nonstable or anticipated to be nonstable) or the participant is unlikely to survive for the duration of the study period.\n* The participant has severe renal organ dysfunction or has known anuria, oliguria, or significant impairment of renal function (creatinine clearance \\\u003C60 mL\u002Fmin or clinically significant elevated serum creatinine as determined by the investigator).\n* The participant has a significant CV history or based on investigator judgment any clinically significant abnormal ECG reading at Screening\u002Fbaseline (e.g., prolonged QT syndrome).\n* The participant is immunocompromised or has altered immune defenses that may predispose the participant to a higher risk of complications (e.g., uncontrolled diabetes in the judgment of the investigator, transplant recipients (with the exception of cornea and autologous BMT), participants with clinically significant persistent granulocytopenia \\[absolute neutrophil count \\\u003C1000\u002FμL\\], and participants receiving immunosuppressive therapy, including corticosteroid therapy at a dose of \\>1 mg\u002Fkg\u002Fday of prednisolone or equivalent for \\>1 week or 0.5-\\\u003C1 mg\u002Fkg\u002Fday prednisolone or equivalent for \\>2 weeks). Participants aged ≥6 years with a known CD4 count of \\\u003C200 cells\u002Fmm3 and participants aged \\\u003C6 years with a known CD4 count of \\\u003C500 cells\u002Fmm3 are to not be enrolled.\n* The participant has any of the following medical condition that requires medication that may be impacted by inhibition of acetylcholinesterase, such as:\n\n  * Poorly controlled asthma or obstructive pulmonary disease at baseline and, in the opinion of the investigator, not stable on current therapy.\n  * Active peptic ulcer disease\n  * Juvenile Parkinson disease\n  * Juvenile Myasthenia gravis\n* The participant has any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study intervention (e.g., ileostomy or malabsorption syndrome).\n* The participant plans to use any of the prohibited medications or nondrug therapies from the Baseline Visit through Follow-up Visit at 7 ±3 days after the single dose of study intervention.\n* The participant has received a prohibited medication within 14 days or 5 half-lives prior to gepotidacin administration, whichever is longer.\n* The participant has been previously enrolled in this study or has previously been treated with gepotidacin.\n* The participant has participated in a clinical trial and has received an investigational product within 30 days or 5 half-lives prior to gepotidacin administration, whichever is longer.\n* The participant, in the judgment of the investigator, would not be able or willing to comply with the protocol or complete study follow-up.\n* If the child is being breastfed:\n\n  * There is suspicion of current alcohol or substance misuse\u002Fabuse in breastfeeding mother.\n  * The breastfeeding mother is taking any medication or any substances containing any of the medications included in the prohibited medication list with known or unknown lactation excretion.\n* The participant has severe hepatic organ dysfunction.\n* The participant has an ALT value \\>2 × ULN.\n* The participant has a total bilirubin \\>1.5xULN; Participants with Gilbert's syndrome can be included with total bilirubin \\>1.5xULN as long as direct bilirubin is ≤1.5xULN.\n* Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.\n* The participant has congenital long QT syndrome or known prolongation of the QTc interval.\n* The participant has uncompensated heart failure.\n* The participant has severe left ventricular hypertrophy.\n* The participant has a family history of QT prolongation or sudden death or history of sudden infant death in a sibling.\n* The participant has a recent history of vasovagal syncope or episodes of symptomatic bradycardia or brady arrhythmia within the last 12 months.\n* The participant is taking QT-prolonging drugs or drugs known to increase the risk of TdP per the ww.crediblemeds.org. \"Known Risk of TdP\" category at the time of the Baseline Visit, which cannot be safely discontinued from the Baseline Visit (Day 1) through 7 (+3) days after the single dose of study intervention; or the participant is taking a strong CYP3A4 inhibitor.\n* The participant has a mean triplicate QTc \\>450 msec or a mean triplicate QTc \\>480 msec for participants with complete bundle branch block.\n* The participant has a documented or recent history of uncorrected hypokalemia within the past 3 months.","2 Years","11 Years",{"count":144,"type":21},20,[94],"The study will be conducted to evaluate how a single oral dose of Gepotidacin is processed in the body over time along with safety monitoring in hospitalized pediatric participants who are receiving a standard of care treatment with antibacterials for a confirmed or suspected infection or for its prevention.",[29],[98,149,150,151,29],"Antibacterial Standard of Care","Antibiotics","Bacterial Infection","2026-04-22",{"date":154,"type":42},"2026-04-23",{"date":156,"type":21},"2026-04-29",{"date":158,"type":21},"2027-08-23",{"name":109,"class":110},{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":168,"minAge":90,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":179,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":192},"100635690","comparing-clean-intermittent-self-catheterization-and-indwelling-catheterization-for-the-management-of-urinary-retention-before-bph-surgery-100635690","NCT07555964","Comparing Clean Intermittent Self-catheterization and Indwelling Catheterization for the Management of Urinary Retention Before BPH Surgery.","Comparing Clean Intermittent Self-catheterization and Indwelling Catheterization for the Management of Urinary Retention Before BPH Surgery.l","CATHETERS","Inclusion Criteria:\n\n* Men over 50 years old;\n* Confirmed diagnosis of benign prostatic hyperplasia (BPH);\n* Prostate volume greater than 40 grams;\n* Presence of acute urinary retention with failure to wean from the catheter despite medical treatment with alpha-blocker for at least 48 hours\n* Indication for surgical management of BPH;\n* Patient affiliated with or a beneficiary of a social security scheme;\n* Signed informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Patient with a history of prostate surgery (including BPH surgery), prostatic artery embolization or Urolift implant placement are not considered a history of prostate surgery;\n* Patient with symptomatic urethral stricture;\n* Patient with a bladder emptying disorder of neurogenic origin;\n* Patient with an anatomical contraindication to ICSC (urethral stricture, false urethral route);\n* Patient who had urine drainage by suprapubic catheter\n* Patient with motor, neurological, anatomical, or cognitive difficulties preventing the education or learning of ICSC;\n* Patient contraindicated for surgical management of their BPH;\n* Patient unable to understand the research documents and provide informed consent;\n* Persons subject to legal protection measures or placed under judicial protection.","MALE",{"count":170,"type":21},106,[24],"The CATHETERS trial is a multicenter, randomized, open-label superiority study comparing two methods of managing urinary retention before surgery for benign prostatic hyperplasia (BPH): clean intermittent self-catheterization (ICSC) versus indwelling catheter (IDC). The primary objective is to determine whether ICSC reduces the occurrence of infectious complications (urinary bacterial colonization requiring antibiotic therapy, urinary tract infection, or urosepsis) compared to IDC in men awaiting BPH surgery. A total of 106 patients will be enrolled across multiple centers in France, with follow-up extending to three months after surgery.",[174,175,176,177,29,178],"Prostatic Hyperplasia","Urinary Retention","Urinary Catheterization","Intermittent Urethral Catheterization","Surgical Procedures",[180,181,182,183],"BPH","ICSC","IDC","Urinary Tractus Infection","2026-04-21",{"date":156,"type":42},{"date":187,"type":21},"2026-04-24",{"date":189,"type":21},"2028-04-24",{"name":191,"class":49},"University Hospital, Bordeaux",5,{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":17,"minAge":201,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":213,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":133},"100626454","effect-of-comprehensive-spa-care-on-kidney-and-urological-conditions-a-clinical-study-in-adult-patients-100626454","NCT07435844","Effect of Comprehensive Spa Care on Kidney and Urological Conditions: A Clinical Study in Adult Patients","Objective Assessment of the Effect of Comprehensive Spa Care on Patients With Chronic Kidney and Urological Diseases: A Prospective Interventional Clinical Study","Uro-Nefro","Inclusion Criteria:\n\n* Male or female aged 40 to 70 years\n* Prescribed comprehensive spa care (KLP) for one of the following indications: recurrent and chronic non-tuberculous inflammation of the kidneys and urinary tract resistant to antibiotic and pharmacological treatment, with at least 12 months of continuous urological care (indication VIII\u002F1); cystic kidney disease (indication VIII\u002F1); nephrolithiasis without urinary tract obstruction or nephrocalcinosis (indication VIII\u002F2); conditions after kidney or urinary tract surgery, including endovesical procedures, complicated prostatectomy, nephrolithotripsy, or recovery after extracorporeal shock wave lithotripsy (indication VIII\u002F3); chronic prostatitis or chronic prostatovesiculitis resistant to pharmacological and antibiotic treatment, with at least 12 months of continuous urological care (indication VIII\u002F4)\n* Able to walk from the sanatorium to the colonnade and back three times daily\n* Willing to follow the treatment plan\n* Signed informed consent\n\nExclusion Criteria:\n\n* Contraindications according to Czech Decree No. 2\u002F2015 Coll. on spa treatment criteria (pregnancy, acute illness, etc.)\n* Significant mobility limitation or severe neuropathy preventing daily walks to the colonnade\n* Significant obesity or inability to briefly hold breath (required for ultrasound examination)\n* Alcohol intake exceeding 20 g of ethanol per day\n* Nephrolithiasis with urinary tract obstruction\n* History of esophageal or gastric variceal bleeding\n* Severe comorbidities that could affect treatment outcomes\n* Active oncological disease\n* Unwillingness to adhere to the treatment plan","40 Years","70 Years",{"count":204,"type":21},150,[24],"This is a single-arm, pretest-posttest study evaluating the effects of a 21-day comprehensive spa care (Komplexní lázeňská léčebně rehabilitační péče, KLP) on patients with nephrological and urological conditions treated at a spa facility in Mariánské Lázně, Czech Republic.\n\nThe study enrolls 150 adult patients (75 men and 75 women), aged 40-70 years, who are prescribed KLP for indications VIII\u002F1 (recurrent and chronic non-tuberculous inflammation of the kidneys and urinary tract), VIII\u002F2 (nephrolithiasis without urinary tract obstruction, nephrocalcinosis), VIII\u002F3 (conditions after kidney and urinary tract surgery), and VIII\u002F4 (chronic prostatitis or prostatovesiculitis resistant to pharmacological treatment).\n\nThe spa treatment consists of the use of natural healing resources of Mariánské Lázně, including a mineral spring drinking cure, balneotherapy (mineral water baths), peloid therapy, carbon dioxide therapy, climatotherapy, exercise therapy, and dietotherapy. The standard treatment duration is 21 days, during which each patient receives a total of 63 therapeutic procedures and drinks mineral spring water three times daily.\n\nPatients undergo assessments at the beginning (days 1-3) and at the end (days 19-21) of their treatment. Assessments include physical examination, abdominal and urinary tract ultrasound, blood and urine sampling with laboratory analysis, body composition measurement using bioelectrical impedance analysis (InBody), and psychometric questionnaire surveys.\n\nThe primary aim of the study is to objectively assess the therapeutic effect of comprehensive spa care on nephrological and urological diseases by comparing pre-treatment and post-treatment clinical, laboratory, and patient-reported outcomes.\n\nThe study was approved by the Ethics Committee of the University Hospital and Faculty of Medicine in Pilsen (decision of November 2, 2023, ref. no. 437\u002F23).",[208,29,209,210,211,212],"Urologic Diseases","Nephrolithiasis","Nephrocalcinosis","Prostatism","Kidney Diseases",[214,215,216,217,218,219,220],"Balneotherapy","Spa Treatment","Mineral Water Drinking Cure","Mariánské Lázně","Nephrology","Urology","comprehensive spa care",{"date":187,"type":42},{"date":223,"type":42},"2026-04-07",{"date":225,"type":21},"2027-04-30",{"name":227,"class":49},"Institute of Spa and Balneology, public research institution",{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":88,"sex":17,"minAge":18,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":240,"conditions":241,"keywords":242,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":92},"100570069","phase-1-a-study-on-the-safety-and-immune-response-of-a-urinary-tract-infection-uti-vaccine-in-adults-18-64-years-of-age-and-clinical-efficacy-in-females-18-64-years-of-age-100570069","NCT06702449","A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age","A Seamless Phase 1\u002F2, Observer-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Immunogenicity of a UTI Vaccine When Administered to Adults 18 Through 64 Years of Age and Clinical Efficacy When Administered to Females 18 Through 64 Years of Age","Inclusion Criteria:\n\n* Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol.\n* Written informed consent obtained from the participant prior to performance of any study-specific procedure.\n* Female participants of non-childbearing potential may be enrolled in the clinical study.\n* Female participants of childbearing potential may be enrolled in the clinical study, if the participant:\n\n  * has practiced adequate contraception for 1 month prior to study intervention administration, and\n  * has a negative pregnancy test on the day of study intervention administration, and\n  * has agreed to continue adequate contraception during the entire treatment period and for at least 1 month after completion of the study intervention administration series.\n* Blood sample for simultaneous follicle stimulating hormone (FSH) and estradiol levels may be collected.\n\nAdditional inclusion criterion only for participants in Part 1 of the study (SLI):\n\n* Female and male between and including 18 through 64 YOA at the time of ICF signature.\n* Healthy participants, according to medical history, laboratory assessment and clinical examination at Screening Visit.\n\nAdditional inclusion criterion only for participants in Part 2 of the study (PoP):\n\n* Females between and including 18 through 64 YOA at the time of ICF signature.\n* Female participants with documented history of at least 1 episode of urine culture confirmed E. coli uncomplicated UTI in the last 12 months prior to study vaccine administration.\n\nExclusion Criteria:\n\nMedical conditions:\n\n* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* Hypersensitivity to latex.\n* History of pIMD.\n* Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.\n* History of endocrinologic, hematologic, metabolic, urologic, dermatologic, or gastrointestinal conditions that, in the opinion of the investigator, places the participant at unacceptable risk or would make adhering to study procedures for the duration of the study difficult.\n* Recurrent history or uncontrolled neurological disorders or any neuroinflammatory (including, but not limited to demyelinating disorders, encephalitis or myelitis of any origin), congenital neurological conditions, encephalopathies, or seizures.\n* Any behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the study.\n* Condition that in the judgment of the investigator would make intramuscular injection unsafe.\n* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.\n\nAdditional exclusionary medical conditions only for participants in Part 1 of the study (SLI):\n\n• Any clinically significant hematologic and\u002For biochemical laboratory abnormality at Screening Visit.\n\nAdditional exclusionary medical conditions only for participants in Part 2 of the study (PoP):\n\n* The participant has UTI that is known or suspected to be due to fungal, parasitic, or viral pathogens; or known or suspected to be due to Pseudomonas aeruginosa or any Enterobacter species.\n* The participant has symptoms known or suspected to be caused by another disease process, such as asymptomatic bacteriuria, overactive bladder, chronic incontinence, or chronic interstitial cystitis, that may interfere with the clinical efficacy assessments.\n* The participant has an anatomical or physiological anomaly that predisposes the participant to UTIs or may be a source of persistent bacterial colonization, including calculi, obstruction or stricture of the urinary tract, primary renal disease or neurogenic bladder, or the participant has a history of anatomical or functional abnormalities of the urinary tract.\n* The participant has an indwelling catheter, nephrostomy, ureteral stent, or other foreign material in the urinary tract.\n* The participant who, in the opinion of the investigator, has an otherwise complicated UTI or has an active upper UTI.\n* Use of any investigational or non-registered product (drug, vaccine or invasive medical device) other than the study intervention(s) during the period beginning 30 days before the first dose of study intervention(s) (Day -29 to Day 1), or their planned use during the study period.\n* Previous administration of a vaccine or immunostimulant targeting rUTI.\n* Participants currently on a prophylactic agent for rUTI (including antibiotics, methenamine, D-mannose).\n* Planned administration and\u002For administration of a vaccine not foreseen by the study protocol in the period starting 15 days before the first dose and ending 15 days after the last dose of study intervention(s) administration.\n* Administration of immunoglobulins and\u002For any blood products or plasma derivatives during the period starting 90 days before the study intervention or planned administration during the study period.\n* Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and\u002For planned use of long-acting immune modifying treatments at any time up to the end of the study.\n\n  * Up to 3 months prior to the study intervention administration:\n  * For corticosteroids, this will mean prednisone equivalent \\>=20 mg\u002Fday for adult participants. Inhaled and topical steroids are allowed.\n  * Up to 3 months prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies, antitumoral medication.\n* Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug, vaccine or invasive medical device).\n* Pregnant or lactating female participant.\n* Female participant planning to become pregnant or planning to discontinue contraceptive precautions before 1 month after completion of the study intervention administration series.\n* History of chronic alcohol consumption and\u002For drug abuse, based on investigator judgment.\n* Persons under guardianship or trusteeship.\n* Persons deprived of liberty.\n* Any study personnel or their immediate dependents, family, or household members.","64 Years",{"count":237,"type":21},448,[94,239],"PHASE2","The purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation of clinical efficacy in females between and including 18-64 YOA.",[29],[243,244,245,246,247,248],"Urinary Tract infection (UTI)","UTI vaccine","E. coli","Safety","Immunogenicity","Efficacy","2026-04-16",{"date":184,"type":42},{"date":252,"type":42},"2024-11-19",{"date":254,"type":21},"2027-05-31",{"name":109,"class":110},{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":89,"minAge":18,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":22,"phases":264,"briefSummary":265,"conditions":266,"keywords":267,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":276,"locationsCount":133},"100591107","application-of-a-prediction-model-for-directing-antibiotic-use-in-the-treatment-of-urinary-tract-infection-in-an-ambulatory-setting-100591107","NCT06976125","Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting","Inclusion Criteria:\n\n* Female sex\n* Age \\>18 years old\n* Discharged from the hospital after ER visit\n* Discharge ICD code consistent with a UTI diagnosis\n* Antibiotic prescribed for UTI at the time of discharge\n\nExclusion Criteria:\n\n* Male sex\n* Necessity for chronic bladder catheterization or discharge with a urinary catheter\n* Patients who have an Emergency Severity Index (ESI) of 1 and 2\n* Patients who verbalize to the study team member that their pain is a 6 or higher\n* Patient set to be transferred to inpatient care\n* History of bladder augmentation\n* Pregnancy (this will be confirmed with a negative pregnancy test which is ordered in the ER)",{"count":263,"type":21},47,[24],"Urinary tract infection (UTI) is when bacteria enter the urinary system and cause an infection. UTIs cause symptoms including burning when peeing, a feeling of an increased urge to pee, and cloudy or strong-smelling urine. Sometimes, severe UTIs can also cause fever, abdominal pain, and\u002For lower back pain.\n\nIn the emergency department (ED), healthcare providers rely on symptoms, along with a urine analysis and a urine culture to diagnose a UTI. A urine analysis involves taking a sample of urine and analyzing different factors like color, acidity, presence of blood cells, presence of bacteria. An abnormal urine analysis increases the likelihood that patients might have a UTI, but it does not confirm it. A positive urine analysis will lead to provider's sending a sample of urine for a urine culture. A urine culture is used to grow whatever bacteria is in the collected urine. If growth is seen on the culture, then this confirms a patient has a UTI. This also specifies which bacteria grew on the culture. The lab can also take it a step further and do an antibiotic test to check which antibiotic the bacteria is sensitive to.\n\nWhen a urine analysis comes back abnormal in an ER setting, patients are prescribed an antibiotic before the culture and antibiotic sensitivity tests come back. If a patients condition is not critical, they will be discharged home before the culture results come back. If the culture comes back positive, the pharmacists will evaluate the culture and antibiotic sensitivity tests, then call patients to inform them whether they are taking a suitable antibiotic.\n\nThis study aims to decrease the unnecessary use of antibiotics because this contributes to antibiotic resistance which is considered a global public health issue. Antibiotic resistance occurs when bacteria develop the ability to withstand certain antibiotics that used to be effective against them, which makes it difficult to treat the infection. One of the factors that increase the risk of antibiotic resistance is the overuse of antibiotics.\n\nIn this study, investigators will be incorporating a prediction model and a negative callback system to decrease unnecessary antibiotic use.",[29],[268,269],"ER visits","Antibiotic use","2026-04-02",{"date":272,"type":42},"2026-04-08",{"date":274,"type":42},"2026-02-20",{"date":75,"type":21},{"name":277,"class":49},"University Hospitals Cleveland Medical Center",{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":89,"minAge":18,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":50},"100631989","electroacupuncture-for-the-prevention-of-recurrent-lower-urinary-tract-infection-in-women-100631989","NCT07507851","Electroacupuncture for the Prevention of Recurrent Lower Urinary Tract Infection in Women","A Randomized Controlled Trial of Electroacupuncture for the Prevention of Recurrent Lower Urinary Tract Infection in Women","rLUTI","Inclusion Criteria:\n\n1. Female patients aged 18-75 years;\n2. Meeting the diagnostic criteria for recurrent lower urinary tract infections;\n3. No acute lower urinary tract infections at enrollment;\n4. Voluntary participation in this trial and signed informed consent. Only patients who meet all the above inclusion criteria can be enrolled in the study.\n\nExclusion Criteria:\n\n1. Currently receiving prophylactic antibiotics for lower urinary tract infection;\n2. Abnormal urinary tract anatomy (e.g., urinary calculi);\n3. Complicated or neurogenic genitourinary disorders, such as spinal cord injury, cauda equina injury, active pelvic inflammatory disease, active vaginitis, overactive bladder, interstitial cystitis;\n4. Requiring urinary catheterization;\n5. HIV infection, long-term use of immunosuppressants, infection with multidrug-resistant organisms, or uncontrolled diabetes mellitus;\n6. Pelvic organ prolapses of grade 2 or above;\n7. Post-void residual urine volume \\> 100 ml measured by B-ultrasound;\n8. Lactating, pregnant, or planning to conceive within the next 6 months;\n9. Implantation of a cardiac pacemaker;\n10. Malignant tumor; severe cardiac, pulmonary, cerebral, hepatic, renal, or hematological diseases, mental illness, or significant cognitive impairment;\n11. Previous history of electroacupuncture treatment;\n12. Subjects with potential poor compliance (e.g., living far from the hospital). Patients meeting any of the above exclusion criteria shall not be enrolled in the study.","75 Years",{"count":288,"type":21},312,[24],"The goal of this clinical trial is to evaluate if electroacupuncture works to prevent recurrent lower urinary tract infections in female patients. It will also learn about the safety of electroacupuncture. The main questions it aims to answer are:\n\n1. Does electroacupuncture reduce the attacks of acute recurrent urinary tract infections in women?\n2. What medical problems do participants have when taking electroacupuncture?\n\nResearchers will compare electroacupuncture to sham electroacupuncture to assess if electroacupuncture works to prevent recurrent lower urinary tract infections.\n\nParticipants will:\n\n1. Take electroacupuncture or sham electroacupuncture for 30 minutes per session over a 6-month period. During the first month, treatment was administered 3 times weekly (once every other day); the second month, 2 times weekly (once every 2-3 days); and the 3-6 month, once monthly.\n2. Visit the hospital at the end of the 1st, 2nd, 3rd, and 6th months for follow-up evaluations.\n3. Keep a diary of their symptoms and the number of times they use an antibiotic.",[29,292,293,294],"Recurrent","Electroacupuncture","Randomized Controlled Trial (RCT)","2026-03-30",{"date":270,"type":42},{"date":298,"type":21},"2026-04",{"date":300,"type":21},"2029-03",{"name":302,"class":49},"Yanjun Zhang, Baoyan Liu",{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":89,"minAge":18,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":50},"100631468","phase-4-prophylactic-antibiotics-for-outpatient-urethral-bulking-100631468","NCT07501065","Prophylactic Antibiotics for Outpatient Urethral Bulking","Prophylactic Antibiotics for Outpatient Urethral Bulking: Impact on Post-Procedural Urinary Tract Infection Rates","Inclusion Criteria:\n\n* Women ≥ 18 years of age.\n* Patients evaluated by a pelvic floor specialist (either urogynecologist or urologist) at the University of Miami with plans to undergo urethral bulking with Bulkamid for stress urinary incontinence or mixed urinary incontinence (stress predominant).\n* Negative testing for UTI in pre-procedural work-up (including either negative urine culture or urine dip negative for infection).\n* Post-void residual volume of 150 mL or less (measured by either catheterization or bladder scan)\n* Fluent in English or Spanish\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Contraindications to both oral antibiotics including antibiotic allergies or significant renal disease (GFR \\\u003C30)\n* Patient undergoing additional pelvic organ prolapse procedures or other urologic procedures concomitantly\n* Recurrent UTIs, defined as 3 or more UTIs within the past 12 months or 2 UTIs within the past 6 months\n* Patients currently taking daily antibiotic prophylaxis for any reason\n* Pelvic organ prolapse stage greater than 2\n* Patients with immunosuppression due to underlying medical conditions\n* Patients who are pregnant\n* Recent antibiotic treatment within one week of the procedure\n* Unable or unwilling to provide informed consent or complete study procedures",{"count":204,"type":21},[312],"PHASE4","The purpose of this study is to evaluate whether taking prophylactic (preventative) antibiotics at the time of standard of care clinic-based urethral bulking reduces the risk of post-procedural urinary tract infection (UTI).",[29,315,316],"Stress Urinary Incontinence","Urinary Incontinence","2026-03-24",{"date":295,"type":42},{"date":320,"type":21},"2026-06",{"date":322,"type":21},"2028-12",{"name":324,"class":49},"University of Miami",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":89,"minAge":18,"maxAge":286,"enrollmentInfo":333,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":336,"conditions":337,"keywords":338,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":353},"100476776","phase-2-a-study-of-lbp-ec01-in-the-treatment-of-acute-uncomplicated-uti-caused-by-drug-resistant-e-coli-eliminate-trial-100476776","NCT05488340","A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)","A Phase 2, Double-blind, Randomized, Active-controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of LBP-EC01 in the Treatment of Acute Uncomplicated Urinary Tract Infection Caused by Drug Resistant E. Coli","ELIMINATE","Inclusion Criteria:\n\n* History of UTI in the past 12 months and prior or current uUTI caused by AMR E. coli (as single pathogen or part of polymicrobial infection where E. coli is the predominant pathogen). Please note that the current infection can be used to meet the requirement of AMR E. coli documentation.\n* Able to supply a mid-stream, clean catch urine sample for microbiological analysis.\n* Active acute uUTI infection defined by:\n\n  a. Evidence of pyuria: i. \\>10 white blood cell (WBC)\u002FmL3 on microscopic evaluation of spun, clean, mid-stream urine specimen or \\>3 WBC\u002Fhigh power field on unspun clean, mid-stream urine specimen, AND\u002FOR ii. Dipstick analysis of a clean, mid-stream urine specimen positive for leukocytes, AND b. At least 2 of the following signs or symptoms of UTI: dysuria, urinary frequency, urinary urgency, or suprapubic pain\n* Willing to comply with all aspects of study design including study restrictions, blood, urine, and stool sampling, and scheduled study visits.\n* All sexually active female patients of childbearing potential must use highly effective contraception during the study and until 2 weeks after the last dose of study drug treatment.\n* Agrees to STOP continuous low dose antimicrobial prophylaxis and\u002For will maintain the same practices for post-coital antimicrobial prophylaxis to prevent UTI, as during the prior 12-months, for the entire study duration (throughout the 6-month follow-up period or study discharge).\n* Agrees to not use any prescription or non-prescription medication for the microbiological or symptomatic treatment of the presenting acute uUTI for the first 10 days of the study.\n* Capable of providing their own signed informed consent form (ICF) prior to any study-related procedures being performed.\n* If participating in Part 1 of the study, agrees to fast for ≥2 h prior to first dose of study drug on Day 1\u002FVisit 1 except for drinking 240 mL of water with study drug administration.\n\nExclusion Criteria:\n\n* Signs or symptoms of systemic illness such as fever greater than 38° Centigrade\u002F Celsius, shaking chills, or other clinical manifestations suggestive of complicated UTI.\n* Treatment with other antibacterial drugs including those that are effective for treatment of the acute uUTI or prevention of recurrent UTI in the 5 days prior to Screening unless the recovered pathogen demonstrates resistance to the initial antibiotic and clinical symptoms persist. In postmenopausal women vaginal estrogen replacement therapy is permitted so long as patient meets all other eligibility criteria, that the dose and regimen has be stable for \\> 3 months from Screening (D1\u002FV1), and that there is no planned change to therapy through the 6-month follow-up period or study discontinuation.\n* Clinical symptoms for more than 5 days before Screening.\n* Presence of indwelling urinary bladder catheters, urinary tract anatomical abnormalities that increase UTI risk or lead to a post void residual (PVR) urine volume \\> 150mL, poorly controlled diabetes mellitus (diagnosed but is not being treated\u002Fmanaged by a physician's care or HbA1c \\>8), current symptomatic or larger than 5mm renal calculi, or advanced renal dysfunction (determined by eGFR \\\u003C 45 mL\u002Fmin\u002F1.73 m2). Patients with vaginal prolapse beyond the hymen with Valsalva (e.g., when coughing).\n* Individuals considered to be immunocompromised.\n* Clinically significant serious unstable physical illness that in the investigator's opinion prevents patient from completing the study or prevents interpretation or resolution of clinical symptoms.\n* Pregnant or nursing women.\n* Exposure to any investigational drugs or other phage therapy 30 days prior to Screening (D1\u002FV1) or prior to participation in this study. Patients who participate in Part 1 are not eligible for participation in Part 2.\n* Allergies to excipients of the study drug or antibiotics.\n* History of autonomic dysreflexia.\n* History of intravenous (IV) drug abuse or is currently using or has positive results for drugs of abuse at screening.\n* Patients who reside in a long-term care facility.\n* Suspected or confirmed acute coronavirus disease 2019 (COVID-19) or recent COVID-19 infection with ongoing symptoms.",{"count":334,"type":21},318,[239],"This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the subsequent 288 patient blinded portion of the study which will be randomized 1:1 comparing LBP-EC01 + antibiotic versus placebo + antibiotic in patients with a history of prior urinary tract infection (UTI) cased by E. coli. All patients will be required to have an active acute uncomplicated UTI at baseline.",[29],[339,36,245,340,341,342,343],"LBP-EC01","Bacteriophage","Phage","crPhage","Recombinant bacteriophage","2026-03-18",{"date":346,"type":42},"2026-03-20",{"date":348,"type":42},"2022-07-13",{"date":350,"type":21},"2026-12",{"name":352,"class":110},"Locus Biosciences",17,{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":22,"phases":363,"briefSummary":364,"conditions":365,"keywords":366,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":133},"100578219","diagnosis-and-treatment-of-urinary-tract-infection-using-dna-polymerase-chain-reaction-versus-urine-culture-100578219","NCT06808451","Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture","Diagnosis and Treatment of Urinary Tract Infection Using DNA PCR Versus Urine Culture - A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult men and women 18 years and older\n* Presenting to clinic with symptoms of UTI or cystitis\n* Patients with Medicare and Medicaid insurance\n\nExclusion Criteria:\n\n* Urinary diversion of any type\n* Chronic indwelling urinary catheter\n* Diagnosed UTI within the previous 21 days\n* Antibiotic therapy within the previous 21 days\n* Use of phenazopyridine within the previous 21 days\n* Commercial insurance\n* Non-English speaking\n* Pregnant patients",{"count":362,"type":21},136,[24],"Adults 18 years or older with urinary tract infection (UTI) symptoms. Participants will be assigned to either the urine culture group or the DNA PCR study group by randomization. At time of enrollment in the study they will be also asked to fill out two questionnaires. If prescribed antibiotics for treatment of a UTI, participants will then be called the day after they are scheduled to stop their antibiotics. Participants will be asked to fill out questionnaires the day after finishing antibiotics. Participants will be enrolled in the study for a maximum of 21 days.",[29],[367,368],"urine culture","DNA PCR","2026-03-10",{"date":371,"type":42},"2026-03-11",{"date":373,"type":42},"2025-10-22",{"date":375,"type":21},"2026-09-30",{"name":277,"class":49},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":22,"phases":386,"briefSummary":387,"conditions":388,"keywords":391,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":404},"100571058","intravenous-versus-oral-treatment-of-the-main-acute-infections-100571058","NCT06715306","Intravenous Versus Oral Treatment of the Main Acute Infections","Intravenous Versus Oral Treatment of the Main Acute Infections in Emergency Departments","Inclusion Criteria:\n\n* Suspected respiratory tract infection, urinary tract infection, or cellulitis by the attending physician\n* Planned or initiated intravenous antibiotic treatment\n\nExclusion Criteria:\n\n* if received more than two doses of intravenous antibiotics;\n* systolic blood pressure \\\u003C90 mmHg;\n* nausea and\u002For vomiting in more than one short-term instance during the last 2 days;\n* suspected significantly reduced gastrointestinal absorption;\n* confirmed plasma-lactate \\> 2;\n* pregnant or nursing;\n* unable to give informed consent;\n* severe immunodeficiency;\n* urgent vital treatment needed.",{"count":385,"type":21},4000,[24],"Patients admitted to the hospital with acute infections are often treated with intravenous (IV) antibiotics. Around 70% of these infections fall into three categories: respiratory tract infections, urinary tract infections, and cellulitis. A Danish study found that 76% of patients admitted with suspected community-acquired pneumonia and treated with antibiotics received them intravenously. Based on an extrapolated estimate from an unpublished local survey, approximately 50,000 patients in Denmark are admitted each year for infections and treated with IV antibiotics. The average hospital stay for these patients is 5.9 days, resulting in a total of 295,000 hospital days annually, accounting for about 7% of total hospital admissions in Denmark. This represents an annual cost of 2.3 billion DKK. While some patients need hospitalization due to their overall health or other serious conditions, others remain hospitalized primarily to receive IV antibiotics.\n\nExpanding the use of oral antibiotics in emergency departments should be pursued only if it can demonstrate comparable efficacy and safety to IV administration. Therefore this study will investigate the efficiency of primarily oral antibiotics in acutely admitted patients with proven or suspected infections. Additionally, the investigators will evaluate the safety of oral regimen for these patients.",[389,29,390],"Respiratory Tract Infections","Cellulitis",[392,393,394],"Oral antibiotic therapy","intravenous antibiotic therapy","intravenous-to-oral-switch","2026-03-03",{"date":397,"type":42},"2026-03-05",{"date":399,"type":42},"2025-01-15",{"date":401,"type":21},"2028-01-06",{"name":403,"class":49},"University of Southern Denmark",7,{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":88,"sex":89,"minAge":412,"maxAge":413,"enrollmentInfo":414,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":416,"conditions":417,"keywords":418,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":133},"100456772","single-dose-amikacin-for-uncomplicated-cystitis-in-the-ed-a-feasibility-study-100456772","NCT05227937","Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study","Single Dose Amikacin for Uncomplicated Cystitis in the Emergency Department (ED): A Feasibility Study","Inclusion Criteria:\n\n* female emergency medicine patients\n* ≥14 years of age\n* uncomplicated urinary tract infection\n* a primary urinary complaint and nitrite-positive urine.\n\nExclusion Criteria:\n\n* pregnancy\n* abnormal genitourinary tract\n* recent urinary tract instrumentation\n* immunosuppression\n* CrCl \\\u003C 25 mL\u002Fmin\n* evidence of pyelonephritis or sepsis\n* any antibiotic treatment within 30 days\n* not available for phone follow-up in 3, 7, and 30 days\n* requires admission to the hospital\n* abnormal mental status.","14 Years","110 Years",{"count":415,"type":21},75,"The purpose of this study is to determine if a single dose of amikacin (a type of antibiotic) can be used to effectively treat emergency department patients with uncomplicated cystitis (inflammation of the bladder). Participating in this study will allow the patient to treat their urinary tract infection (UTI) with a single intramuscular (IM (into the arm)) or intravenous (IV (into the vein)) shot of amikacin, rather than having to go to the pharmacy to pick up a prescription for antibiotics, and then take antibiotics for 3-7 days. A single dose of amikacin has been demonstrated to be safe, effective and well tolerated in other studies, but some patients may decline to participate because they do not wish to have an IV or IM shot, or because they don't want to speak on the phone with a research assistant three times over the next 30 days.",[29],[419,420,421],"urinary tract infections","amikacin","emergency medicine","2026-03-02",{"date":424,"type":42},"2026-03-04",{"date":426,"type":42},"2022-09-21",{"date":428,"type":21},"2026-12-31",{"name":430,"class":49},"Antonios Likourezos",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":89,"minAge":18,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":22,"phases":439,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":133},"100570719","early-phase-1-vitamin-c-and-hiprex-in-ruti-100570719","NCT06710899","Vitamin C and Hiprex in rUTI","Does Vitamin C Improve the Efficacy of Methenamine Hippurate (Hiprex®) in Prophylaxis of Recurrent Urinary Tract Infections? A Proof of Concept Study","Inclusion Criteria:\n\n* Female\n* Age ≥18 years\n* Recurrent proven UTI, defined as \"two or more proven infections in six months or three or more infections in six months\"\n* Willing and able to give fully informed consent\n* Patients suitable for prophylaxis following discussion with their clinician.\n* No contra-indications to treatment with methenamine hippurate or Vitamin C\n* All women will have undergone standard diagnostic work-up and have followed routine conservative UTI prevention measures.\n* A working email address to be used to submit urine pH results\n* Willing and able to comply with the study procedures\n* Females of childbearing potential must be willing to use a highly effective method of contraception (hormonal or barrier method of birth control; abstinence; sterilisation or vasectomised partner)\n\nExclusion Criteria:\n\n* Males\n* Women who are pregnant or breast-feeding\n* Contraindications to methenamine hippurate as described in BNF: known allergy, gout, severe metabolic acidosis, severe dehydration, eGFR less than 10 ml\u002Fmin, severe hepatic impairment\n* Currently using vitamin C containing supplement or cranberry extract tablets\n* Women using urinary alkalinisation agents, e.g potassium citrate, sodium bicarbonate\n* Currently receiving any form of bladder instillation or intradetrusor Onabotulinum Toxin A injections\n* Patients already on low-dose antibiotics or methenamine hippurate (due to delay that will be incurred by 3-month washout period)\n* Indwelling urinary catheter in situ or performing clean intermittent self-catheterisation\n* Correctable urinary tract abnormalities, e.g., urinary tract calculi, urinary retention\n* Formation of ileal conduit or augmented bladder\n* Neurogenic bladder dysfunction\n* Hyperoxaluria",{"count":144,"type":21},[440],"EARLY_PHASE1","A single centre proof of concept study to assess whether Vitamin C improves the efficacy of Methenamine Hippurate (Hiprex®) in the prophylaxis of recurrent urinary tract infections (rUTIs) in women",[29],"2026-02-10",{"date":445,"type":42},"2026-02-11",{"date":447,"type":21},"2027-01",{"date":449,"type":21},"2028-01",{"name":451,"class":49},"University Hospitals of North Midlands NHS Trust",{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":202,"enrollmentInfo":460,"targetDuration":4,"studyType":22,"phases":462,"briefSummary":463,"conditions":464,"keywords":465,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":133},"100623213","metaphylaxis-of-infected-kidney-stones-after-percutaneous-nephrolithotripsy-100623213","NCT07393711","Metaphylaxis of Infected Kidney Stones After Percutaneous Nephrolithotripsy","Evaluation of the Effectiveness of Intrarenal Dioxidine Metaphylaxis for Preventing Recurrence of Infection Stones After Percutaneous Nephrolithotripsy","DIOX-PCNL","Inclusion Criteria:\n\nAge ≥18 years\n\nPatients undergoing percutaneous nephrolithotripsy (PCNL)\n\nInfection-related kidney stones\n\nAbility to provide written informed consent\n\nExclusion Criteria:\n\nAge \\\u003C18 years\n\nPregnancy or breastfeeding\n\nKnown hypersensitivity to dioxidine\n\nSevere renal insufficiency or end-stage renal disease\n\nSevere comorbid conditions that preclude participation",{"count":461,"type":21},95,[24],"Kidney stone recurrence, particularly infection-related stones, remains a significant clinical problem after percutaneous nephrolithotripsy (PCNL). Bacterial colonization and persistent infection are recognized contributors to stone recurrence.\n\nThis study evaluates the effectiveness of intrarenal dioxidine instillation as a metaphylactic measure to reduce recurrence of infection-related kidney stones following PCNL. Patients undergoing PCNL will receive standard treatment, with or without adjunctive intrarenal dioxidine administration. The study aims to assess whether this approach reduces stone recurrence and infection-related complications.",[27,209,29],[466,467,468,469,470,471,472,473],"Percutaneous nephrolithotomy","PCNL","Infection stones","Struvite stones","Dioxidine","Intrarenal instillation","Stone recurrence","Metaphylaxis","2026-02-08",{"date":445,"type":42},{"date":477,"type":21},"2026-03-01",{"date":479,"type":21},"2026-12-30",{"name":481,"class":49},"West Kazakhstan Marat Ospanov Medical University",{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":489,"enrollmentInfo":490,"targetDuration":4,"studyType":22,"phases":492,"briefSummary":493,"conditions":494,"keywords":496,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":4},"100622334","evaluation-of-safety-and-efficacy-of-phage-therapy-for-drug-resistant-bacterial-infections-an-exploratory-prospective-single-arm-study-100622334","NCT07382271","Evaluation of Safety and Efficacy of Phage Therapy for Drug-resistant Bacterial Infections: An Exploratory, Prospective Single-arm Study","Phage Therapy","Inclusion Criteria:\n\n* 1\\. Aged 18-65 years old. 2. Patients with urinary tract infections caused by drug-resistant bacteria (based on drug susceptibility test results from our hospital or other Grade A tertiary hospitals).\n\n  3\\. The pathogenic bacteria infected by the patient must meet one of the following conditions:\n  1. Pathogenic bacteria are resistant to key antibiotics:\n\n     ① Acinetobacter baumannii: carbapenem-resistant;\n     * Enterobacteriaceae (e.g., Klebsiella pneumoniae, Escherichia coli): carbapenem or cephalosporin-resistant;\n\n       * Pseudomonas aeruginosa: carbapenem-resistant;\n\n         * Enterococci: vancomycin-resistant; ⑤ Staphylococcus aureus: methicillin or vancomycin-resistant; ⑥ Stenotrophomonas maltophilia. Referenced to the WHO Bacterial Priority Pathogens List, 2024\n  2. The pathogenic bacteria are sensitive to key antibiotics in vitro, but treatment with such antibiotics is ineffective or shows insignificant efficacy (the patient's target bacterial infection persists for 7 days or more, and the infection cannot be eradicated despite antibiotic administration during this period).\n  3. The use of key antibiotics to which the pathogenic bacteria are sensitive is restricted (e.g., potential organ toxicity caused by the antibiotics, or the patient is allergic to such antibiotics).\n\n     4\\. At least one lytic phage targeting the pathogenic bacteria can be screened out.\n\n     5\\. The patient can tolerate the procedures of intravesical perfusion via urinary catheter, retrograde pyeloperfusion via ureteral catheter, or pyeloperfusion via percutaneous nephrostomy tube, and agrees to receive indwelling or intermittent catheterization during the treatment period.\n\n     6\\. The subject and their family members (or legal guardian) have fully read and understood the relevant information, and signed the informed consent form.\n\n     Exclusion Criteria:\n* 1\\. Bacterial infection controllable with conventional antibiotic therapy. 2. Presence of undrained urinary tract abscess or obstruction. 3. Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²). 4. Concurrent organ failure (heart, liver, lung, etc.). 5. Severe autoimmune diseases. 6. No available phages active against the infecting pathogen. 7. Other conditions deemed unsuitable by the investigator.","65 Years",{"count":491,"type":21},6,[24],"This study is an investigator-initiated, single-center, exploratory clinical trial designed to evaluate the safety and efficacy of phage therapy in patients with urinary tract infections caused by drug-resistant bacteria.\n\nEligible patients aged 18 to 65 years will receive the phage cocktail intervention according to a predefined dosage regimen, with a treatment course of 2 to 3 days and a follow-up period of 2 to 4 weeks after treatment. The primary outcome measures include the incidence of adverse events during treatment, the pathogen clearance rate, and the improvement of clinical symptoms (e.g., fever, local inflammation).\n\nThe purpose of this study is to provide a scientific basis for the subsequent clinical application of this phage cocktail, and to explore a novel therapeutic option for patients with drug-resistant bacterial infections who have shown poor responses to conventional antibiotic therapy. All participants will undergo standardized medical monitoring throughout the trial, and their rights and safety will be fully protected by the Institutional Review Board (IRB) during the entire process.",[29,495],"Urinary Tract Infections Caused by Drug-resistant Bacteria",[487,497,36,498],"Drug-resistant bacteria","Personalized phage cocktail","2026-01-25",{"date":501,"type":42},"2026-02-02",{"date":503,"type":21},"2026-02",{"date":505,"type":21},"2026-08",{"name":507,"class":49},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":518,"briefSummary":519,"conditions":520,"keywords":524,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":538},"100475513","follow-up-automatically-vs-as-needed-comparison-faan-c-trial-100475513","NCT05471908","Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial","The Follow-up Automatically vs. As-Needed Comparison Trial","FAAN-C","Inclusion Criteria:\n\n* Age \\\u003C18 years at the time of randomization\n* Hospitalization due to a primary diagnosis of pneumonia, skin and soft tissue infection, acute gastroenteritis, or urinary tract infection.\n* Parent speaks English or Spanish.\n\nExclusion Criteria:\n\n* Presence of a comorbid disease that is both chronic and complex\n* Principal disease required surgical intervention (beyond superficial incision and drainage)\n* Immunodeficiency\n* A well-child check-up or post-hospitalization follow-up visit is already scheduled within 7 days of hospital discharge\n* Parent or participant strongly prefers PRN or automatic follow-up\n* A medical provider feels strongly that a post-hospitalization follow-up visit is needed within 7 days of hospital discharge\n* Sibling concurrently hospitalized\n* Unable to identify a clinic where the participant would receive any needed post-hospitalization follow-up\n* Diagnosis of pneumonia complicated by:\n\n  o Receiving a chest tube\n* Diagnosis of urinary tract infection complicated by:\n\n  * History of neurogenic bladder or urologic surgery\n  * Renal imaging anticipated within 7 days of hospital discharge\n  * Renal abscess\n* Diagnosis of skin and soft tissue infection complicated by:\n\n  * Chronic wound\n  * Postoperative infection\n  * Predisposition to poor wound healing\n  * Discharging with a drain in place\n  * Complicated by necrotizing fasciitis or toxic shock syndrome\n* Diagnosis of gastroenteritis complicated by:\n\n  * Hemolytic uremic syndrome",{"count":517,"type":21},2674,[24],"Compare the effectiveness of automatic vs as-needed (PRN) post-hospitalization follow-up for children who are hospitalized for common infections.",[521,29,522,523],"Pneumonia","Soft Tissue Infections","Gastroenteritis",[525,526,527,528],"post-hospitalization","follow-up care","patient centered care","randomized control trial","2025-12-03",{"date":531,"type":42},"2025-12-10",{"date":533,"type":42},"2022-08-22",{"date":535,"type":21},"2028-02-28",{"name":537,"class":49},"University of Utah",14,{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":89,"minAge":18,"maxAge":546,"enrollmentInfo":547,"targetDuration":4,"studyType":22,"phases":549,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":558,"locationsCount":133},"100455127","phase-4-nextgen---clinical-implication-of-next-generation-sequencing-100455127","NCT05206500","NextGen - Clinical Implication of Next Generation Sequencing","Clinical Implication of Next Generation Sequencing of Urinary Bacteria in Patients With Low Colony Forming Units of Bacteria in Traditional Urine Culture","Inclusion Criteria:\n\n* Female at least 18 years of age\n* U\u002FC (Urinary Culture) growth of \\\u003C10,000 Colony-Forming Units (CFU)\n* Understanding and acceptance of the need to return for all scheduled follow-up visits\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Catheter in use (Foley or suprapubic or intermittent)\n* Not able to provide clean midstream urine\n* Antibiotic consumption in the past 2 weeks before signing the consent\n* Pregnant or Planning to Conceive\n* Incarcerated","80 Years",{"count":548,"type":21},100,[312],"Recently more advanced techniques, including Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) are available to detect bacteria in urine based on bacterial genomes. Comparing to traditional culture, these techniques have more sensitivity and could potentially be of a great help in patients with Colony Count of less than 10,000 and more than zero.",[29],"2025-12-01",{"date":554,"type":42},"2025-12-08",{"date":556,"type":42},"2022-05-17",{"date":322,"type":21},{"name":559,"class":49},"Wake Forest University Health Sciences",{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":22,"phases":570,"briefSummary":571,"conditions":572,"keywords":574,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":80},"100569056","physical-rehabilitation-of-older-persons-following-a-community-acquired-infection-hospitalization---a-randomised-controlled-trial-100569056","NCT06689280","Physical Rehabilitation of Older Persons Following a Community-Acquired Infection Hospitalization - A Randomised-Controlled Trial","Physical Rehabilitation of Older Persons Following a Community-Acquired Infection Hospitalization: A Feasibility Study","REHAB-CAI","Inclusion Criteria:\n\n* Patients aged ≥65 years or 18-64 years if the presence of at least one chronic disease (e.g., diabetes, COPD, heart failure, etc.)\n* Suspicious of a lower respiratory tract infection AND\n* Presence of one or more symptoms of a lower respiratory tract infection such as fever ≥38.3°C, hypothermia \\\u003C35.0°C, new onset of cough, pleuritic chest pain, dyspnea, or altered breath sounds on auscultation.\n* Positive urine nitrate test and\u002For leukocyturia as depicted by positive esterase test or microscopy AND\n* Presence of one or more symptoms of urinary tract infection such as dysuria, urgent or frequent urination, perineal or suprapubic pain, costo-vertebral tenderness or flank pain, fever (ear or rectal temperature of ≥38.2°C or axillary temperature of ≥38.0°C), or history of feeling feverish with shivering or rigors in the past 24 hours.\n* Functionally independent before hospitalization and expected to be discharged to their own homes.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Hospitalization within the past 14 days.\n* Inability to participate in the study due to dementia, paralysis, or other disorders.\n* Severe aortic valve stenosis or terminal illness.\n* Unstable cardiac arrhythmic disease.\n* High risk for non-adherence as determined by screening evaluation.\n* Already participating in regular exercise training.\n* Unable to understand Danish.\n* Unwilling or unable to give informed consent.",{"count":569,"type":21},460,[24],"Community-acquired infections such as community-acquired pneumonia (CAP) and urinary tract infection (UTI) remain leading causes of hospitalization and death due to infections in older persons in Europe. Hospitalization often results in further disabilities and frailty for older and frail individuals, from which some may never recover. Physical activity is well-established as a cornerstone in the primary prevention and treatment of several noncommunicable diseases. However, there is currently no established rehabilitation model following a pneumonia or other infection, nor is there any evidence to support the impact of rehabilitation on the mental and physical health of older and frail individuals following a pneumonia hospitalization or other infection.\n\nThe aim of the feasibility study is to evaluate a patient-centered and individualized exercise intervention that is kick-started during hospitalization and continued for 3 months after discharge with video-supervised home-based exercise training to patients hospitalized with CAP or UTI compared to standard care with regard to safety, clinical outcomes, patients' perception, functional ability, organizational aspects, and economic aspects.",[573,29],"Community-acquired Pneumonia",[575,576],"CAP","UTI","2025-11-26",{"date":579,"type":42},"2025-12-02",{"date":581,"type":21},"2026-01-01",{"date":583,"type":21},"2029-12-31",{"name":585,"class":49},"Nordsjaellands Hospital",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":593,"targetDuration":595,"studyType":61,"phases":4,"briefSummary":596,"conditions":597,"keywords":604,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":616,"locationsCount":50},"100573775","the-impact-of-de-implementing-urine-dipsticks-for-diagnosis-of-utis-in-hospitals-100573775","NCT06750666","The Impact of De-implementing Urine Dipsticks for Diagnosis of UTIs in Hospitals","The Impact of De-implementing Urine Dipsticks for Diagnosis of Urinary Tract Infections in the North Denmark Region: An Interrupted Time-series Analysis","Inclusion Criteria:\n\n* All patients admitted to emergency rooms (≥18 years) from 2019 and forward.\n\nExclusion Criteria:\n\n* Patients directly admitted to an inpatient unit without first visiting an emergency room are excluded from the study.\n* For the primary analysis, only the first admission will be included; subsequent admissions will be excluded.",{"count":594,"type":21},480000,"30 Days","The goal of this interrupted time-series analysis is to evaluate the impact of the de-implementation of urine dipsticks as a diagnostic tool for urinary tract infections (UTIs) in hospitalized patients in the North Denmark Region. The main question it aims to answer is:\n\nHow does de-implementation of urine dipsticks affect the diagnosis and management of UTIs and related disorders?\n\nSpecifically, does it change the following parameters:\n\n* Number and severity of UTI infections (lower and upper UTI, non-severe and severe)\n* Antibiotic prescription (overall, antibiotic classes, administration routes, duration, dosages)\n* Number of urine cultures and number of positive urine cultures\n* Risks of admission to intensive care units and 30-day mortality\n* Risk of drug toxicity\n* Length of hospital stay\n* Risk of admission to intensive care unit\n* 30-day risk of readmission after discharge\n* 6-month risks of Clostridioides difficile enterocolitis and de novo antimicrobial resistance in cultures obtained during routine clinical care.\n\nResearchers hypothesize that de-implementing urine dipsticks will lead to a reduced frequency of diagnosed cystitis, reduced antibiotic use, and fewer urine cultures without negatively affecting patient mortality or readmission risk.\n\nResearchers will compare the outcomes before and after the discontinuation of urine dipsticks across hospitals in the North Denmark Region. Furthermore, results will be compared to another Danish administrative healthcare region where dipsticks are still in use as well as urine culture data from the primary sector in the North Denmark Region.\n\nSince this is a registry-based observational study utilizing data from the electronic patient record system in the North Denmark Region, no direct contact will be made with participants.",[29,598,599,600,601,602,603],"Diagnostic Techniques and Procedures","Point-of-Care Testing","Anti-Bacterial Agents","Registry","Clinical Decision-making","Urinalysis",[605,29,606,607,608,609],"Urine Dipstick De-implementation","Hospital","Registry-Based Study","Clinical Impact","urine dipsticks","2025-09-30",{"date":612,"type":42},"2025-10-01",{"date":614,"type":21},"2025-12",{"date":350,"type":21},{"name":617,"class":49},"Jacob Bodilsen",{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":88,"sex":17,"minAge":18,"maxAge":625,"enrollmentInfo":626,"targetDuration":4,"studyType":22,"phases":628,"briefSummary":629,"conditions":630,"keywords":633,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":635,"startDateStruct":637,"completionDateStruct":639,"leadSponsor":641,"locationsCount":133},"100608879","phase-1-phase-i-study-of-singlemultiple-ascending-doses-of-jkn2501-for-injection-in-chinese-healthy-volunteers-100608879","NCT07207291","Phase I Study of Single\u002FMultiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers","A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers","Inclusion Criteria:\n\n* Voluntary informed consent; able to comply with study requirements and communicate effectively.\n* Healthy subjects aged 18-45 years (inclusive) at screening.\n* BMI 19.0-26.0 kg\u002Fm² (inclusive); weight ≥50 kg (male) or ≥45 kg (female).\n* Vital signs, physical examination, ECG, laboratory tests, chest X-ray, and abdominal ultrasound results judged as normal or clinically insignificant by the investigator.\n* Agreement to use effective non-pharmaceutical contraception from signing ICF until 90 days after last dose; no sperm\u002Fegg donation plans during this period.\n\nExclusion Criteria:\n\n* Pregnant\u002Flactating women; positive pregnancy test; unprotected sex within 2 weeks prior to dosing.\n* Investigator-determined history or presence of clinically significant disorder that may affect safety or trial participation.\n* Use of drugs known to inhibit\u002Finduce hepatic metabolism within 4 weeks, or any medication (prescription, OTC, herbal, vitamins) within 2 weeks prior to dosing; planned use during the trial.\n* Major surgery within 3 months prior to screening or planned during trial; history of surgery potentially affecting results.\n* History of febrile illness or active infection within 2 weeks prior to screening.\n* Blood loss\u002Fdonation \\>400 mL within 3 months prior to screening, or received blood products; plans to donate blood during trial or within 30 days after last dose.\n* History of significant food\u002Fdrug allergy, or allergy to JKN2501\u002Fexcipients.\n* Excessive alcohol consumption; inability to abstain from alcohol from 48h pre-dose until end of study.\n* Smoking ≥5 cigarettes\u002Fday within 3 months prior to screening; inability to abstain from smoking from 48h pre-dose until end of study.\n* History of drug abuse; positive urine drug screen at baseline (Day -1).\n* Positive alcohol breath test at baseline (Day -1).\n* Participation in another interventional clinical trial within 3 months prior to screening or planned during this trial.\n* Estimated glomerular filtration rate (eGFR) \\\u003C90 mL\u002Fmin.\n* Serum total calcium below lower limit of normal at screening.\n* Investigator-determined unsuitable venous access for PK sampling\u002Finfusion, or history of adverse symptoms\u002Fphobias related to infusion\u002Fphlebotomy.\n* Excessive daily intake of tea, coffee, or caffeinated beverages within 3 months prior to screening.\n* Consumption of grapefruit, Seville oranges, caffeine, or xanthine-rich foods\u002Fbeverages within 48h prior to first dose; inability to abstain during the trial.\n* History of QTc prolongation; or investigator-determined clinically significant ECG abnormalities at screening\u002Fbaseline.\n* Any other condition deemed by the investigator to make the subject unsuitable for participation.","45 Years",{"count":627,"type":21},66,[94],"This Phase I study is a randomized, double-blind, placebo-controlled, dose-escalation trial conducted at a single center. It consists of two parts:\n\nPart 1 (SAD): Evaluates the safety, tolerability, and pharmacokinetics (PK) of single ascending intravenous doses of JKN2501 in healthy adults. Biological samples (blood, urine, feces) will be collected for PK analysis.\n\nPart 2 (MAD): Evaluates the safety, tolerability, and PK of multiple ascending intravenous doses of JKN2501 in healthy adults.\n\nDose levels may be adjusted based on emerging safety, tolerability, and PK data from preceding cohorts.",[631,29,632,389],"Bacterial Infections","Intra-Abdominal Infections",[631],"2025-09-28",{"date":636,"type":42},"2025-10-03",{"date":638,"type":42},"2025-08-22",{"date":640,"type":21},"2026-03-19",{"name":642,"class":110},"Joincare Pharmaceutical Group Industry Co., Ltd",{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":649,"eligibilityCriteria":650,"healthyVolunteers":12,"sex":89,"minAge":201,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":22,"phases":652,"briefSummary":653,"conditions":654,"keywords":656,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":675,"completionDateStruct":677,"leadSponsor":679,"locationsCount":133},"100607277","phase-4-microbiome-modulating-prophylaxis-rct-antibiotic-vs-gynoflor-in-postmenopausal-women-with-recurrent-cystitis-100607277","NCT07186465","Microbiome-Modulating Prophylaxis RCT: Antibiotic vs Gynoflor in Postmenopausal Women With Recurrent Cystitis","Evaluating Urinary Microbiome Modulation :An RCT of Antibiotic vs Gynoflor Prophylaxis in Postmenopausal Women With Recurrent Cystitis","microbiome","Inclusion Criteria:\n\n* Female, postmenopausal, age ≥40 years\n* Clinical history of recurrent urinary tract infection (rUTI) as assessed by the investigator\n* Able and willing to take assigned prophylaxis for 6 months\n* Able to attend baseline and Month 6 study visits and provide urine samples\n* Able to provide written informed consent\n* Willing and able to complete twice-weekly phone\u002FLINE follow-ups\n\nExclusion Criteria:\n\n* Current symptomatic UTI at enrollment (may be treated and reconsidered after resolution)\n* Known hypersensitivity or contraindication to nitrofurantoin or to the Lactobacillus\u002Festriol vaginal tablet (Gynoflor) or their excipients; significant renal impairment or other label-based contraindications to nitrofurantoin per local practice\n* Planned urologic surgery or procedure expected during the 6-month study period\n* Recent bacterial vaginosis (e.g., within the past month) or active vulvovaginal skin disorders precluding vaginal product use\n* History of hormone-dependent malignancy (e.g., breast, uterine, or cervical cancer) or unexplained abnormal vaginal bleeding\n* Significant liver disease (e.g., active hepatitis) or other conditions judged by the investigator to make participation unsafe\n* Participation in another interventional trial that could interfere with outcomes\n* Withdrawal of consent or severe adverse event requiring discontinuation",{"count":548,"type":21},[312],"This open-label, parallel-group randomized controlled trial compares two prophylaxis strategies for recurrent urinary tract infection (rUTI) in postmenopausal women: (1) nightly oral nitrofurantoin 100 mg for 6 months versus (2) a vaginal tablet containing Lactobacillus with ultra-low-dose estriol (Gynoflor: nightly for 14 days, then twice weekly to month 6). Participants (≥40 years) are randomized 1:1 in computer-generated blocks and followed for 6 months. The primary endpoint is the proportion with rUTI recurrence within 6 months. Secondary endpoints include time to first recurrence, antibiotic resistance in breakthrough infections, change in lower urinary tract symptoms (Thai RUTISS), and urinary microbiome measures (Lactobacillus dominance and community diversity by qPCR and 16S rRNA). Key assessments occur at baseline and month 6 (urinalysis, culture, urinary microbiome sampling, and kidney function). Adherence and adverse events are captured via twice-weekly phone\u002FLine contacts. Approximately 100 participants (50 per arm) will be enrolled as a feasibility-sized pilot.",[655,29],"Cystitis, Recurrent",[657,658,659,660,661,662,663,664,665,666,667,668,669,670,671],"Postmenopausal Women","Nitrofurantoin","Antibiotic Prophylaxis","Gynoflor","Lactobacillus","Estriol","Vaginal Probiotics","Urinary Microbiome","16S rRNA Sequencing","qPCR","Lower Urinary Tract Symptoms","RUTISS Questionnaire","Adherence Monitoring","Antimicrobial Resistance","Thailand","2025-09-22",{"date":674,"type":42},"2025-09-25",{"date":676,"type":42},"2025-09-11",{"date":678,"type":21},"2026-08-30",{"name":680,"class":49},"Mahidol University",{"id":682,"slug":683,"hasResults":12,"nctId":684,"briefTitle":685,"officialTitle":686,"acronym":687,"eligibilityCriteria":688,"healthyVolunteers":12,"sex":17,"minAge":689,"maxAge":690,"enrollmentInfo":691,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":693,"conditions":694,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":696,"lastUpdatePostDateStruct":697,"startDateStruct":699,"completionDateStruct":701,"leadSponsor":703,"locationsCount":144},"100349136","research-of-the-consequences-on-the-digestive-tract-following-the-proposed-treatments-for-a-urinary-infection-in-children-100349136","NCT03825874","Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children","Comparison of the Impact on Digestive Portage of Broad Spectrum Beta-Lactamase-Producing Enterobacteriaceae (E-ESBLs) of Proposed Treatments in Outbreaks of Childhood Urinary Tract Infection","MIKA","Inclusion Criteria:\n\n* Infant and child (age ≥ 3 months and \\\u003C3 years)\n* Patient treated for febrile urinary tract infection as monotherapy with amikacin IV, ceftriaxone (IV or IM) or cefixime PO \\*\n* Whose parents read and understood the newsletter and whose express consent was collected\n* Patient affiliated to a social security scheme (Social Security or Universal Medical Coverage)\n\nExclusion Criteria:\n\n* Child treated with more than one antibiotic (eg treatment with dual therapy ceftriaxone \u002F cefotaxime and aminoglycoside)\n* Antibiotherapy in progress or discontinued in the previous 7 days\n* Hospitalized child\n* Refusal of one of the parents","3 Months","3 Years",{"count":692,"type":21},200,"The emergence of extended-spectrum beta-lactamase-producing Enterobacteriaceae (E-ESBL) is a major public health problem. It leads more frequent prescription of penems with the risk of emergence and spread of strains producing carbapenemases, which may be resistant to all known antibiotics. A policy of savings of penems is desirable. Among the alternatives to penems, amikacin is in the foreground. It remains active on the majority of E-ESBL strains. Some risk factors for E-ESBL emergence are known: recent antibiotic therapy (particularly quinolones and cephalosporins third generation), previous hospitalization or residence in a high endemic country.\n\nIn pediatrics, E-ESBLs are primarily responsible for urinary tract infection. In France, E-ESBLs represent about 10% of the strains responsible for urinary tract infections. The Pathology Group Pediatric Infectious (GPIP) of the French Society of Pediatrics (SFP) and the Society of Infectious Pathology French Language (SPILF) have proposed different therapeutic options to treat febrile UTIs in children: amikacin intravenous; intravenous (IV) ceftriaxone or intramuscular (IM); or cefixime per-os (PO).\n\nThe objective of this study is to compare the emergence of E-ESBLs in stools of children after febrile UTIs treatment with amikacin IV versus ceftriaxone or cefixime.",[29,695],"Urinary Tract Infections in Children","2025-08-26",{"date":698,"type":42},"2025-08-27",{"date":700,"type":42},"2019-01-19",{"date":702,"type":21},"2026-07",{"name":79,"class":49}]